{
    "clinical_study": {
        "@rank": "137682", 
        "arm_group": [
            {
                "arm_group_label": "THIAA", 
                "arm_group_type": "Experimental", 
                "description": "Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day.\nStage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to Placebo arm receive the placebo tablet, 3 times a day.\nStage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to Placebo arm receive the placebo tablet, 3 times a day."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this 2-stage intervention study is to investigate the effect of a novel\n      nutraceutical (containing tetrahydro iso-alpha acids derived from hops) on weight loss and\n      weight loss maintenance in obese participants."
        }, 
        "brief_title": "Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Weight Loss"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI \u2265 30 and \u2264 47\n\n        Exclusion Criteria:\n\n          -  Prohibited medications, supplements or herbal products\n\n               1. Use of narcotics, oral or injectable corticosteroids, multivitamin/multimineral\n                  supplements, antioxidant supplements, vitamin D supplements, probiotics and\n                  omega-3 fatty acid supplements 30 days prior to screening and for the duration\n                  of the study.\n\n               2. Use of prescription medications and/or nonprescription medications for acute\n                  medical conditions, semi-acute medical conditions, and weight loss.\n\n               3. Change in prescription, OTC, nutritional supplements and or medical foods within\n                  30 days prior to the beginning of the study and for the duration of the study.\n\n          -  Medical history and concurrent diseases\n\n               1. Known allergy or hypersensitivity to study product or placebo.\n\n               2. Clinically significant abnormalities in medical history of physical examination.\n\n               3. Clinically relevant conditions expected to preclude achievement of exercise\n                  recommendation.\n\n               4. Hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrinologic,\n                  neurologic, immunologic, or hematologic disease.\n\n               5. Diabetes mellitus, irritable bowel syndrome, Gastro-esophageal reflux disease,\n                  HIV, TB ,hepatitis B or C, malignancy, sleep apnea, insomnia (requiring use of\n                  sleeping medication more than once weekly), night eating syndrome, Anorexia\n                  nervosa, bulimia, of non-specific eating disorder, and serious psychiatric\n                  illness.\n\n               6. Smoking or use of nicotine containing products within 30 days prior to screening\n                  and for the duration of the study.\n\n               7. Use of drugs of abuse (e.g. marijuana, cocaine, PCP, and methamphetamine) within\n                  30 days prior to screening and for the duration of the study.\n\n          -  Other criteria\n\n               1. Initiation of a new or change of an existing exercise regiment within 30 days\n                  prior to screening.\n\n               2. Initiation of a new or change of an existing food plan within 30 days prior to\n                  screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656681", 
            "org_study_id": "WLM1-FMR-CT"
        }, 
        "intervention": [
            {
                "arm_group_label": "THIAA", 
                "description": "A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day", 
                "intervention_name": "THIAA", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tablet", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 6, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gig Harbor", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98332"
                }, 
                "name": "Functional Medicine Research Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 64-week Pilot Trial to Evaluate the Effects of a Novel Nutraceutical on Weight Loss and Weight Loss Maintenance in Obese Subjects", 
        "overall_official": {
            "affiliation": "MetaProteomics / Metagenics", 
            "last_name": "Joseph J Lamb, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the absolute pounds of weight change from baseline to the end of the 64 weeks.", 
            "measure": "Weight loss maintenance", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 64 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656681"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent weight loss at the end of 12 weeks (i.e. the Stage 1 of the trial where subjects participate in HP2).", 
                "measure": "Weight loss", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks"
            }, 
            {
                "description": "Absolute amount of weight loss at the end of 12 weeks (i.e. the Stage 1 of the trial where subjects participate in HP2).", 
                "measure": "Weight loss", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks"
            }, 
            {
                "description": "Comparing the difference in absolute amount of weight loss between 2 arms at the end of 12 weeks (i.e. the Stage 1 of the trial).", 
                "measure": "Short-term THIAA effect", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks"
            }, 
            {
                "description": "Comparing the difference in percent weight loss between 2 arms at the end of 12 weeks (i.e. the Stage 1 of the trial).", 
                "measure": "Short-term THIAA effect", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks"
            }, 
            {
                "description": "To evaluate absolute amount of weight loss during Stage 2 of the trial where subjects participate in MLGL (i.e. 12 weeks to 64 weeks).", 
                "measure": "Weight loss", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 64 weeks"
            }, 
            {
                "description": "To evaluate percent weight loss during Stage 2 of the trial where subjects participate in MLGL (i.e. 12 weeks to 64 weeks).", 
                "measure": "Weight loss", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 64 weeks"
            }, 
            {
                "description": "To evaluate the difference between 2 arms the amount of weight loss during the trial (i.e. baseline to 64 weeks).", 
                "measure": "Long-term THIAA effect", 
                "safety_issue": "No", 
                "time_frame": "baseline, 64 weeks"
            }
        ], 
        "source": "MetaProteomics LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MetaProteomics LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}